Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center

BACKGROUND: Few data are available on the safety of COVID-19 vaccines in cancer patients undergoing active cancer-directed treatment. PATIENTS AND METHODS: This case series analyzes outcomes in terms of adverse events in 5297 patients undergoing anti-cancer treatment who were vaccinated with anti-SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunello, Antonella, Guarneri, Valentina, Coppola, Marina, Bernardi, Matteo, Ottolitri, Ketti, Ghi, Maria Grazia, Mioranza, Eleonora, Vianello, Federica, Gottardi, Michele, Lonardi, Sara, Zagonel, Vittorina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895736/
https://www.ncbi.nlm.nih.gov/pubmed/35641217
http://dx.doi.org/10.1093/oncolo/oyab037
Descripción
Sumario:BACKGROUND: Few data are available on the safety of COVID-19 vaccines in cancer patients undergoing active cancer-directed treatment. PATIENTS AND METHODS: This case series analyzes outcomes in terms of adverse events in 5297 patients undergoing anti-cancer treatment who were vaccinated with anti-SARS-CoV-2 Pfizer-BioNTech vaccine at a single cancer center from March 6, 2021 to May 9, 2021. Adverse events were retrieved from the national Italian pharmacovigilance platform (http://www.vigicovid.it). RESULTS: Of the 5297 patients treated for either solid tumors (87%) or onco-hematologic malignancies (13%) who were vaccinated, 8 adverse drug reactions (ADRs) were reported. One was a severe ADR and 7 were non-severe ADRs. Non-severe ADRs resolved within 48 hours. CONCLUSION: BNT162b2 Pfizer-BioNTech vaccine was safely administered in the largest cohort of cancer patients reported to date.

Ejemplares similares